NCT06973629Phase 3Not yet recruiting

Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)

Study sponsor: Brainstorm-Cell Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-11-01Estimated
Enrollment · participants200Estimated
Source updated2025-05-22Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.